Innovation Without Limits
The Shenzhen SME Service Bureau recently announced the 2025 list of designated "Specialized, Refined, Differentiated, and Novel" (SRDN) small and medium enterprises. Shenzhen Medgen Life Science Co., Ltd. earned this prestigious designation on the strength of its sustained technological innovation and solid industry expertise.
Deep Specialization
Since its founding in 2017, Medgen has remained focused on biomaterials, regenerative engineering, and translational medicine. Built on two core technology platforms — "hydroxyapatite regenerative product development" and "biomedical collagen crosslinking technology" — the company conducts systematic, specialized product R&D and industrialization efforts.
Medgen has persisted in its high-performance biomaterials niche, progressively building a complete technology chain from material synthesis and process optimization to clinical validation, establishing significant technological barriers and first-mover advantages.
Product Achievements
Leveraging its two core technology platforms, Medgen has successfully developed a series of regenerative repair products including pre-filled artificial bone (BoneSwift™) and oral bone graft material (PoroGraft®), with broad applications across bone defect repair, oral bone augmentation, and other clinical scenarios. Through rigorous quality control systems and standardized production processes, the company ensures stable and reliable product performance, providing clinicians with safe and effective solutions.
The company upholds a spirit of "self-improvement and pioneering innovation," emphasizing the rapid translation of cutting-edge research into practical applications. Throughout the product development process, Medgen continuously advances technology iterations and process optimization, strengthening its technological barriers and market competitiveness.
Looking Ahead
Receiving the Shenzhen "SRDN" SME designation is both a recognition of Medgen's eight years of focused development and an encouragement for future growth.
Medgen will continue to increase R&D investment, deepen core technology platform development, expand its product pipeline, accelerate capacity expansion and market promotion, and maintain its focus on biomaterials and regenerative medicine. The company is committed to injecting new momentum into the high-quality development of Shenzhen's and China's biomedical industry, fulfilling its corporate mission of "providing patients and society with superior medical products and professional services."